Advertisement

Topics

Companies Related to "Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation" [Most Relevant Company Matches] RSS

20:45 EST 21st February 2019 | BioPortfolio

Here are the most relevant search results for "Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation" found in our extensive corporate database of over 50,000 company records.

Showing "Visilizumab Prevention Graft versus Host Disease After Allogeneic" Companies 1–25 of 3,300+

Extremely Relevant

MaaT Pharma

MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leuk...


Kiadis Pharma N.V.

Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The Company believes that its innovative products have the potential to address the current risks and limitations connected with allo...

Ariad Pharmaceuticals Incorporated

ARIAD Pharmaceuticals, Inc. is focused on the discovery and development of novel and proprietary drugs based on its understanding of the inner-workings of cells and the genes involved in disease. The Company has developed a product based on its gene regulation technology to treat graft-versus-host disease, a complication of bone marrow transplantation involving an attack by a patient's immune syst...


Soligenix, Inc.

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec(®) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute ...

Relevant

Stemedica International S.A.

Founded in Epalinges, Switzerland, in 2008, Stemedica International S.A. is a global biotechnology company that develops therapeutic applications for the treatment and prevention of Alzheimer’s disease and vascular dementia. The company is a subsidiary of Stemedica Cell Technologies, Inc., a global biotechnology company that manufactures adult allogeneic ...

DOR BioPharma

DOR BioPharma, Inc. is a biopharmaceutical company addressing life-threatening side effects of cancer and cancer treatments, serious gastrointestinal diseases and disorders, and biomedical countermeasures. Our lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD)...

Gene Signal

Gene Signal (www.genesignal.com) is developing a robust pipeline of novel antisense oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions based on its innovative angiogenesis modulating technology. The company’s most advanced therapeutic product is aganirsen (GS-101), an antisense oligonucleotide that has nearly completed...

Apogenix GmbH

The biopharmaceutical company Apogenix, located in Heidelberg, Germany, develops innovative drug candidates which exert their therapeutic effect by modulating the programmed cell death (apoptosis). The therapeutic focus lies on acute cerebro- and cardiovascular diseases (e.g. myocardial infarction) where apoptosis is abnormally increased, and on cancer diseases where apoptosis is abnormally decrea...

Artegraft, Inc.

Incorporated in 1993, Artegraft, Inc. offers surgeons a biological alternative to synthetic grafts. Artegraft’s natural collagen matrix has proven long-term patency advantages over ePTFE and other synthetic graft materials. Artegraft is also positioned as an alternative to a non-viable autogenous fistula. Artegraft was the first vascular graft a...

Targazyme, Inc.

Targazyme, Inc. is a privately held biotechnology company based in San Antonio, TX with additional offices in San Diego, CA and Basel, Switzerland. Its key technology platforms (TZ101 and TZ102) are designed to improve the homing and engraftment of a wide variety of therapeutic cells to target tissues. Applications in development include hematopoietic stem...

Alzheimer's Research and Prevention Foundation

The Alzheimer's Research and Prevention Foundation (ARPF) is a non-profit organization dedicated to reducing the incidence of Alzheimer's disease by conducting clinical research and providing educational outreach about the lifestyle changes that can help prevent Alzheimer's disease. For more information, please visit the Alzheimer's Research and Prevention Foundation at www.alzheimersprevention.o...

Yale-Griffin Prevention Research Center

The Yale-Griffin Prevention Research Center (PRC) was established in 1998 through funding from the Centers for Disease Control (CDC). One of 35 such centers nationwide representing academic/community partnerships, the Yale-Griffin PRC is engaged in interdisciplinary applied prevention research in collaboration with community partners, federal, state, and local health and education agencies, and ot...

Bioheart Incorporated

Bioheart is focused on treatment and prevention of heart attacks and cardiovascular disease by developing: cellular implants for regeneration of heart muscle;genetic tests for directing customization of heart disease prevention and therapeutic care plans; andheart health nutritional products

Cancer Prevention Pharmaceuticals, Inc.

Cancer Prevention Pharmaceuticals, Inc. (CPP) is developing therapeutics designed to reduce the risk of cancer and other diseases. CPP’s pharmaco-prevention approach has been used with success in other disease categories such as cardiovascular, neurovascular, and infectious disease. In addition to the CPP FAP-310 trial, CPP is co-sponsoring with the N...

Allogene Therapeutics, Inc.

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therap...

SIRAKOSS Ltd

SIRAKOSS is developing nanosynthetic graft substitutes to facilitate complete bone repair and transform patient healing. The SIRAKOSS bone graft substitutes utilise advanced and proprietary understanding of nanostructures and nanochemistry to catalyze faster bone regeneration coupled with total graft resorption. SIRAKOSS was spun out of the University of A...

American Liver Foundation

The American Liver Foundation is the nation’s largest non-profit organization focused solely on promoting liver health and disease prevention. The mission of the American Liver Foundation is to facilitate, advocate and promote education, support and research for the prevention, treatment and cure of liver disease.

InnAVasc, Inc.

InnAVasc Medical, Inc. is a medical device company founded by Duke University surgeons and scientists, which designs and develops products for vascular and hemodialysis access. The Company’s first technology is an arteriovenous graft (AVG) modification that incorporates two multilayer cannulation chambers, with self-sealing technology, that are resist...

ApaTech, Inc.

ApaTech is a world leader in synthetic bone graft technologies. Our mission is to provide surgeons with superior, proprietary, bone graft solutions, helping them improve clinical outcomes and patient quality of life. ApaTech was formed in 2001 with the rights to bone materials research and IP from London and Cambridge Universities. The company retains pipeline agreements with founding inventors, i...

SystemOne

Founded in Massachusetts in 2012, SystemOne focuses on producing solutions for disease surveillance and response. SystemOne has offices in Springfield, MA and Johannesburg, South Africa. The company’s new disease intelligence software, Aspect®, addresses numerous infectious diseases including Zika, Ebola, HIV, Malaria, Hepatitis C and more on a hos...

National Sports Concussion Cooperative

The NSCC will host a group of industry experts to discuss sports concussions, research on concussion prevention and the effects these injuries can have on all stakeholders: players and their families, coaches, sports medicine professionals and helmet manufacturers.

Smittskyddsinstitutet (SMI)

The Swedish Institute for Infectious Disease Control (SMI) is a government expert authority with a mission to monitor the epidemiology of infectious disease among Swedish citizens and promote control and prevention of these diseases.SMI collaborates with several government authorities and other organisations within the field of infectious disease control and prevention. The most important contacts...

NeoMatrix, LLC

Based in Irvine, Calif., NeoMatrix© develops innovative devices that allow women and their doctors to promote optimal breast health. The company's premier product, the HALO Breast Pap Test System, is the first fully automated, noninvasive breast cancer risk assessment tool designed for use in the primary care office setting. The System has been FDA cleared for the collection of nipple aspirate fl...

Visterra, Inc.

Visterra discovers and develops novel drugs for the prevention and treatment of major diseases. The company’s proprietary platform generates unique structural information that identifies novel drug target sites and guides the design of drugs to effectively combat disease. The company’s lead product candidate, VIS410, is a broad spectrum monoclona...

Visterra Inc.

Visterra discovers and develops novel drugs for the prevention and treatment of major diseases. The company’s proprietary platform generates unique structural information that identifies novel drug target sites and guides the design of drugs to effectively combat disease. The company’s lead product candidate, VIS410, is a broad spectrum monoclona...


More From BioPortfolio on "Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks